Synergetic impact of lipoprotein(a) and fibrinogen on stroke in coronary artery disease patients

Cheng Yang,Cheng‐Gang Zhu,Yong‐Gang Sui,Yuan‐Lin Guo,Na‐Qiong Wu,Qian Dong,Rui‐Xia Xu,Jie Qian,Jian‐Jun Li
DOI: https://doi.org/10.1111/eci.14179
2024-02-18
European Journal of Clinical Investigation
Abstract:Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease. This prospective study on 8263 stable coronary artery disease (CAD) patients revealed that elevated Lp(a) combined with fibrinogen (Fib) significantly increased the risk of ischemic stroke beyond individual effects. Notably, Lp(a)‐high and Fib‐high had the highest risk (adjusted HR 4.325, 95% CI: 1.902–9.79) compared to Lp(a)‐high or Fib‐high alone. Combining Lp(a) with Fib improved predictive significance, highlighting their synergistic impact on ischemic stroke risk in patients with CAD. Background Emerging data suggested that lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease. Previous studies indicated fibrinogen (Fib) had synergetic effect on Lp(a)‐induced events. However, combined impact of Fib and Lp(a) on ischemic stroke has not been elucidated. Methods In this prospective study, we consecutively enrolled 8263 patients with stable coronary artery diseases (CAD) from 2011 to 2017. Patients were categorized into three groups according to tertiles of Lp(a) levels [Lp(a)‐low, Lp(a)‐medium, and Lp(a)‐high] and further divided into nine groups by Lp(a) and Fib levels. All subjects were followed up for the occurrence of ischemic stroke. Results During a median follow‐up of 37.7 months, 157 (1.9%) ischemic strokes occurred. Stroke incidence increased by Lp(a) (1.1 vs. 2.1 vs. 2.5%, Cochran‐Armitage p
medicine, general & internal, research & experimental
What problem does this paper attempt to address?